ReportGem ReportGem

U.S. COMPANY FILING

REGENERON PHARMACEUTICALS, INC. — Form 10-Q filed 2026-04-29

Filed: 2026-04-29Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNExchange: NasdaqForm: 10-QReport period: 2026-03-31SEC accession: 0000872589-26-000016Event: earningsMateriality: 85

Filing text preview

Regeneron's Q1 2026 revenue rose 19% to $3.61B, but net income fell 10% to $727M due to higher costs and a lower gross margin from a manufacturing interruption. EYLEA HD grew, while EYLEA declined. The company authorized an additional $3B buyback and declared a $0.94 dividend.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-04-29Why Regeneron (REGN) Is Up 5.4% After FDA Approves Pasatru For Ultra-Rare FOP Therapy2026-08-20FDA Approves Regeneron's (REGN) Pasatru for Ultra-Rare FOP in August 2026; Shares Up 5.4%2026-08-2010-Q2026-07-30 · 10-Q8-K2026-07-30 · 8-K8-K2026-04-29 · 8-K10-K2026-02-04 · 10-K8-K2026-01-30 · 8-K